APRI Calculator
Calculate your AST to Platelet Ratio Index (APRI) to help assess liver fibrosis risk from lab results.
What Is the APRI Score?
The AST to Platelet Ratio Index (APRI) is a non-invasive scoring system used to estimate the likelihood of liver fibrosis in patients with chronic liver disease. It combines two routine lab values—aspartate aminotransferase (AST) and platelet count—into a single index that correlates with fibrosis stage.
Developed as an alternative to liver biopsy, the APRI score helps clinicians identify patients who may have significant fibrosis or cirrhosis without requiring an invasive procedure. It is most commonly used in the context of chronic hepatitis C, hepatitis B, and non-alcoholic fatty liver disease (NAFLD).
How the APRI Score Is Calculated
The APRI formula uses the patient's AST level relative to the upper limit of normal (ULN), divided by the platelet count. The standard calculation is:
APRI = (AST ÷ ULN) ÷ Platelet Count × 100
Where:
- AST is measured in U/L (units per liter)
- ULN is the upper limit of normal for AST, typically 40 U/L
- Platelet Count is measured in 10⁹/L
The result is a decimal value that corresponds to different probabilities of fibrosis severity. Most clinical guidelines use an APRI threshold of 0.5 to suggest significant fibrosis and 1.0 to suggest cirrhosis.
How to Use the APRI Calculator
Enter your most recent lab results into the calculator fields. You will need:
- Your AST value (from a comprehensive metabolic panel or liver function test)
- Your platelet count (from a complete blood count)
The calculator automatically applies the standard APRI formula and displays the resulting score. No additional inputs or adjustments are required.
Understanding Your APRI Result
The APRI score is interpreted against established clinical thresholds:
- APRI < 0.5 – Low probability of significant fibrosis. Further evaluation may not be immediately necessary.
- APRI 0.5 – 1.0 – Indeterminate range. Additional testing or follow-up may be warranted.
- APRI > 1.0 – High probability of significant fibrosis or cirrhosis. Further diagnostic workup is typically recommended.
These thresholds are based on large-scale validation studies and are referenced in clinical practice guidelines from organizations such as the World Health Organization and the American Association for the Study of Liver Diseases.
Limitations of the APRI Score
While the APRI score is a useful screening tool, it has important limitations:
- It is less accurate in patients with acute liver injury, where AST may be transiently elevated
- Platelet counts can be affected by conditions unrelated to liver disease, such as immune disorders or medications
- The score has lower sensitivity and specificity compared to more advanced non-invasive tests like FibroScan or FIB-4
- It may not reliably distinguish between intermediate stages of fibrosis
The APRI score should be interpreted in the context of the full clinical picture, including medical history, physical examination, and other diagnostic findings.
Common Clinical Use Cases
The APRI calculator is most frequently used in the following scenarios:
- Initial assessment of liver fibrosis in patients with chronic hepatitis C or B
- Monitoring disease progression over time in patients with chronic liver disease
- Screening for cirrhosis in primary care or resource-limited settings
- Pre-treatment evaluation before antiviral therapy
In many clinical protocols, APRI is used alongside other non-invasive markers to improve diagnostic accuracy.
FAQ
What does APRI stand for?
APRI stands for AST to Platelet Ratio Index. It is a calculated score used to assess the likelihood of liver fibrosis.
What is the normal range for APRI?
There is no single "normal" APRI value. A score below 0.5 is generally considered low risk for significant fibrosis. Scores above 1.0 suggest a high probability of cirrhosis.
Can APRI replace a liver biopsy?
No. APRI is a screening tool, not a replacement for liver biopsy. It helps identify patients who may need further evaluation but does not provide the same level of detail as histological examination.
Is the APRI score accurate for all types of liver disease?
APRI has been most extensively validated in chronic hepatitis C and B. Its accuracy may be lower in other liver conditions, particularly those involving acute inflammation or extrahepatic causes of thrombocytopenia.
How often should APRI be checked?
The frequency of APRI testing depends on the underlying condition and treatment plan. In chronic liver disease, it may be repeated every 6 to 12 months to monitor for disease progression.